<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yao Q</submitter><funding>The National Key Research and Development Program of China</funding><funding>The Open Funds of the State Key Laboratory of Veterinary Aetiological Biology, Lanzhou Vet-erinary Research Institute, Chinese Academy of Agricultural Sciences</funding><funding>The National Natural Science Foundation of China</funding><pagination>1953</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9367258</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(15)</volume><pubmed_abstract>&lt;i>C. parvum&lt;/i> is an important diarrheal pathogen in humans and animals, especially in young hosts. To accurately and rapidly detect &lt;i>C. parvum&lt;/i> infection in calves, we established a nano-PCR assay targeting the &lt;i>cgd3_330&lt;/i> gene for the specific detection of &lt;i>C. parvum&lt;/i>. This nano-PCR assay was ten times more sensitive than that of the normal PCR assay by applying the same primers and did not cross-react with &lt;i>C. andersoni&lt;/i>, &lt;i>C. bovis&lt;/i>, &lt;i>C. ryanae&lt;/i>, &lt;i>Balantidium coli&lt;/i>, &lt;i&gt;Enterocytozoon bieneusi&lt;/i>, &lt;i>Giardia lamblia&lt;/i>, and &lt;i>Blastocystis&lt;/i> sp. To further test the nano-PCR in clinical settings, a total of 20 faecal samples from calves were examined by using the nano-PCR, the normal PCR, and the nested PCR assays. The positive rates were 30% (6/20), 30% (6/20), and 25% (5/20) for the nano-PCR, the normal PCR, and the nested PCR assays, respectively, indicating that the nano-PCR and the normal PCR assays had the same positive rate (30%). Taken together, the present study could provide a candidate method for the specific detection of &lt;i>C. parvum&lt;/i> infection in calves in clinical settings.</pubmed_abstract><journal>Animals : an open access journal from MDPI</journal><pubmed_title>Development and Preliminary Evaluation of a Nanoparticle-Assisted PCR Assay for the Detection of &lt;i>Cryptosporidium parvum&lt;/i> in Calves.</pubmed_title><pmcid>PMC9367258</pmcid><funding_grant_id>SKLVEB2020KFKT015</funding_grant_id><funding_grant_id>2017YFD0501305</funding_grant_id><funding_grant_id>32072890</funding_grant_id><pubmed_authors>Yang X</pubmed_authors><pubmed_authors>Huang S</pubmed_authors><pubmed_authors>Zhao G</pubmed_authors><pubmed_authors>Yao Q</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Song J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Development and Preliminary Evaluation of a Nanoparticle-Assisted PCR Assay for the Detection of &lt;i>Cryptosporidium parvum&lt;/i> in Calves.</name><description>&lt;i>C. parvum&lt;/i> is an important diarrheal pathogen in humans and animals, especially in young hosts. To accurately and rapidly detect &lt;i>C. parvum&lt;/i> infection in calves, we established a nano-PCR assay targeting the &lt;i>cgd3_330&lt;/i> gene for the specific detection of &lt;i>C. parvum&lt;/i>. This nano-PCR assay was ten times more sensitive than that of the normal PCR assay by applying the same primers and did not cross-react with &lt;i>C. andersoni&lt;/i>, &lt;i>C. bovis&lt;/i>, &lt;i>C. ryanae&lt;/i>, &lt;i>Balantidium coli&lt;/i>, &lt;i&gt;Enterocytozoon bieneusi&lt;/i>, &lt;i>Giardia lamblia&lt;/i>, and &lt;i>Blastocystis&lt;/i> sp. To further test the nano-PCR in clinical settings, a total of 20 faecal samples from calves were examined by using the nano-PCR, the normal PCR, and the nested PCR assays. The positive rates were 30% (6/20), 30% (6/20), and 25% (5/20) for the nano-PCR, the normal PCR, and the nested PCR assays, respectively, indicating that the nano-PCR and the normal PCR assays had the same positive rate (30%). Taken together, the present study could provide a candidate method for the specific detection of &lt;i>C. parvum&lt;/i> infection in calves in clinical settings.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Aug</publication><modification>2025-04-05T08:56:23.861Z</modification><creation>2025-02-19T03:32:22.666Z</creation></dates><accession>S-EPMC9367258</accession><cross_references><pubmed>35953942</pubmed><doi>10.3390/ani12151953</doi></cross_references></HashMap>